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Abstract
Background: While the incidence of pertussis has increased in adolescents and adults in recent years in the U.S.,
little is known about the incidence and economic burden of pertussis in older adults. This study provides evidence
of the incidence of pertussis and direct medical charges associated with pertussis episodes of care (PEOCs) in adults
aged 50 years and older in the U.S.
Methods: PEOCs were divided into periods before and after the initial pertussis diagnosis was made (i.e., the index
date) to capture any conditions immediately preceding the pertussis diagnosis that may have represented
misdiagnoses and subsequent conditions that may have represented sequelae. Data were extracted from IMS's
recently acquired SDI databases of longitudinal, patient-level practitioner claims and hospital operational billing
records collected from private practitioners and hospitals, respectively, across the U.S. Patients 50 years and older
with one or more ICD-9-CM diagnoses for pertussis/whooping cough and/or a laboratory test positive for
Bordetella pertussis between 1/1/2006 and 10/31/2010 were eligible for study inclusion. Resource utilization and
charges (i.e., unadjudicated claims) associated with the patient's physician and hospital care were analyzed. The
nationally projected incidence of pertussis was estimated using a subsample of patients with the required data
necessary for projection.
Results: Estimated incidence of diagnosed pertussis ranged from 2.1-4.6 cases per 100,000 people across the two
age groups (50–64 and [greater than or equal to] 65) during the years 2006 to 2010. The analysis of charges
included 5,748 patients [greater than or equal to] 50 years of age with pertussis. Average charges across the entire
episode of care were $1,835 and $14,428 per patient in the outpatient and inpatient settings, respectively. The
average number of outpatient (i.e., private practitioner) visits was 2 per patient in both the pre-index and
post-index periods.
Conclusions: In the U.S., the incidence of diagnosed pertussis in adults 50 years and older has increased between
2006 and 2010. Healthcare utilization and charges associated with pertussis are substantial, suggesting the need for
additional prevention and control strategies and a higher degree of clinical awareness on the part of health care
providers. Additional research regarding pertussis in older populations is needed to substantiate these findings.
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Background
Pertussis (whooping cough) is a contagious respiratory
illness caused by the bacterium Bordetella pertussis [1].
Before vaccines to prevent the disease were available,
pertussis was a major cause of morbidity and mortality
in U.S. children. The historical information regarding
pertussis in adults suggests that cases were rare and/or
underreported. Following the universal recommenda-
tion of diphtheria, whole-cell pertussis and tetanus
(DPT) vaccines in U.S. children, a sharp decline in cases
was observed for many decades. In recent decades,
however, reported pertussis cases have been steadily in-
creasing in the U.S. where pediatric vaccination rates
remain high [2,3]. Additionally, the age range of affected
individuals appears to have widened and reported cases
have disproportionately increased in adolescents and
adults [4-6]. In the U.S., pertussis now represents the least
well controlled of all bacterial vaccine-preventable diseases
for which universal childhood immunization is recom-
mended [7,8].
Unlike many diseases for which immunization is recom-
mended, neither a completed immunization series in child-
hood nor natural infection confer lifelong immunity [9-11],
and thus poses additional challenges for prevention and
control. Reported duration of immunity varies widely be-
tween studies but may be shorter than previously thought
[9,12,13]. Pertussis susceptibility and infection in adults is a
concern not only with respect to morbidity but also for the
potential transmission risk to non-immune infants who are
particularly vulnerable to complications and mortality [14].
Indeed, adults are an important source of B. pertussis in-
fection in infants and children [15].
Until 2005, pertussis-containing vaccines were not
indicated for use in adolescents or adults and only very
recently (i.e., 2010) was a pertussis-containing vaccine
recommended for adults over the age of 64. The Advis-
ory Committee on Immunization Practices (ACIP) cur-
rently recommends that a one-time dose of Tdap
(tetanus toxoid, reduced diphtheria toxoid, and acellular
pertussis) vaccine is administered to all adults who have
not received Tdap previously or for whom vaccine sta-
tus is unknown to replace one of the 10-year tetanus
and diphtheria (Td) boosters, and as soon as feasible to
the following groups of adults who have not received
Tdap previously or for whom vaccine status is un-
known: 1) pregnant (>20 weeks gestation) or postpar-
tum women, 2) close contacts of infants younger than
age 12 months (e.g., grandparents and child-care provi-
ders), and 3) health-care personnel [16].
The recent resurgence of pertussis is well established
[1,2,11,14,17,18] and while it appears that a wider age
range is affected, little is known about the incidence or
burden of pertussis in adults and the elderly. An under-
standing of the incidence and burden of pertussis in
these populations is necessary for developing effective
clinical approaches and public health programs to curb
the spread of pertussis.
The primary objective of this study was to estimate the
incidence and describe the burden of pertussis in a popu-
lation that was not traditionally thought of as being
affected by the disease (i.e., older adults). We examined
the clinical presentation of and physician coding behaviors
associated with pertussis as well as assessed reported
charges from pertussis-related inpatient and outpatient
healthcare utilization.
Methods
A retrospective, observational study was conducted to es-
timate the incidence of diagnosed pertussis among adults
50 years and older in the U.S. and obtain descriptive data
on the clinical burden and healthcare associated charges
of pertussis episodes of care in this population.
Data sources
Data were extracted from IMS’s U.S. databases, recently
acquired from SDI, including private practitioner med-
ical claims, hospital charge detail master data (a database
of patient-level accounting records), and commercial
outpatient laboratory test results. IMS data are accessible
to researchers through grants, academic discounts and
for general purchase.
The private practitioner medical claims database
(CMS-1500) captures diagnoses and procedures across
all types of payers for insured patients. This database
comprises approximately 1 billion entries and over 80
million claims per year (~ two-thirds of all electronically
filed medical claims in the U.S.) submitted by more than
870,000 physicians per month. Between 1/1/2006 and
10/31/2010, over 102 million unique patients aged
50 years old or older were observed in the private practi-
tioner medical claims database. Hospital charge detail
master (CDM) data are daily transactional patient
charges from over 450 hospitals, representing over 9% of
all nonfederal, acute and short-stay hospitals in the U.S.
Between 1/1/2006 and 10/31/2010, over 35 million
unique patients aged 50 years old or older were observed
in the hospital database. Available data attributes include
detailed drug, procedure, device, diagnosis, and applied
charges information for each patient’s stay. In addition,
patient demographics and admission/discharge charac-
teristics are available. Data were also extracted from
commercial outpatient laboratory test results represent-
ing approximately 40% of all commercial laboratory test-
ing performed in the U.S. Patient-level data in this study
were de-identified. All databases utilized in the current
study were certified as being compliant with the Health
Insurance Portability and Accountability Act (HIPAA).




To assess healthcare utilization and charges, patients with
at least one of the ICD-9-CM pertussis/whooping cough
diagnoses [033.0 (whooping cough due to B. pertussis),
033.9 (whooping cough, organism unspecified), 484.3
(pneumonia in whooping cough)] or a positive laboratory
test for B. pertussis (i.e., Polymerase Chain Reaction; PCR,
antigen detection, culture or single sera IgA, IgG, and or
IgM titers) between 1/1/2006 and 10/31/2010 were eligible
for inclusion. If more than one inclusion criterion was
present on the index date (i.e., the first confirmation ─
diagnosis or positive laboratory result ─ of pertussis
within the study period), the following hierarchy was ap-
plied: hospital diagnosis, private practitioner diagnosis
with preferred order 033.0, 033.9, then 484.3, and lastly
positive laboratory result.
Patients with a positive B. pertussis laboratory test re-
sult were indexed to the date of specimen collection that
yielded the pertussis-positive result. These patients must
also have had a medical claim (from a hospital or private
practitioner’s office) with a pertussis-related diagnosis
and a date of service within 14 days of the collection of
the laboratory test specimen to be included. Diagnoses
were considered to be pertussis-like or related based on
existing literature, clinical opinions, and/or internal data
distributions of diagnoses made during the periods im-
mediately before and immediately following the pertussis
diagnosis. Examples of pertussis-like diagnoses included
cough and upper and lower respiratory tract infections
and pertussis related diagnoses included fractured ribs.
To ensure patients were observable throughout the
duration of their episode of care, the study required
observed healthcare activity from at least 3 months be-
fore to at least 3 months after the index date for each
patient indexed to a private practitioner (CMS-1500)
claim. Likewise, to ensure stability of the data reporting
source (i.e., the practitioner or hospital), consistent claim
submission during pre-index and post-index periods was
required. Additional patient inclusion criteria included a
known gender and age of 50 years or older at the time
of initial diagnosis (i.e., the index date).
Weighted sample
Pertussis incidence was defined as the nationally pro-
jected number of patients with a new pertussis diagnosis
(i.e., 033.0, 033.9 and/or 484.3) from the private practi-
tioner database. The projected incidence was calculated
using IMS’s medical data projection weights (see also
Toback et al. [19]) to provide a nationally representative
estimate of pertussis cases diagnosed in private practi-
tioner offices between 2006 and 2010. The weights were
estimated by month and physician specialty strata. The
universe of office-based American Medical Association
(AMA) practitioners (contained in the AMA master file
[20]) was divided by the corresponding number of practi-
tioners in the IMS sample. To ensure accuracy of the
weighted incidence estimates, only practitioners whose
sample activity was deemed representative of their specialty
and who had relevant longitudinal continuity were
included in the sample. Private practitioners whose data
was used to create projection factors during the period of
study represented between 9% (annual average in 2006)
and 17% (annual average in 2010) of all general practice,
internal medicine, and geriatric specialists in the nation. In-
cidence rates per 100,000 persons were calculated by divid-
ing the nationally projected number of diagnosed pertussis
cases by the U.S. Census populations [21] according to age
group and year and multiplying the product by 100,000.
Estimated incidence rates were compared to incidence
rates of pertussis in the U.S. population aged 65 years old
and older reported to the Nationally Notifiable Disease
Surveillance System (NNDSS). The comparison was
expressed as a ratio of the IMS incidence rate to the
NNDSS rate by year from 2006 through 2010.
Data analysis
To capture resource utilization and charges likely asso-
ciated with pertussis (i.e., pertussis-like illness) before
the initial diagnosis, we examined the frequency of each
patient’s medical visits during the six month period be-
fore pertussis was diagnosed and used a hierarchical lin-
ear mixed model to compute a patient-specific cutoff
which was one standard deviation above the patient’s
mean interval (days) between visits. Visits for pertussis-
like illness occurring between the index date and this in-
dividual cutoff defined the pre-index period for each pa-
tient. The end of each patient’s episode was defined as
the visit date that preceded a 30-day period free of any
pertussis-related diagnosis. Episode lengths were capped
at 180 days based on the clinical opinion that pertussis
episodes of care should resolve within 6 months and that
longer episodes were likely be indicative of chronic/
underlying conditions. Nearly all patients (99.5%) had
episodes of care equal to or less than 180 days.
A descriptive analysis of demographic and health status
information was undertaken. The unit of analysis was the
patient and as these results were reported at the raw,
observed level, they cannot be assumed to be nationally
representative. Counts of patients and the percent of the
total per category were summarized for demographic and
health status variables. Analysis of Variance (ANOVA) was
used to assess differences in patient characteristics of
interest. All post hoc tests employed Bonferroni adjust-
ments for multiple comparisons. Additional measures of
central tendency and variability were calculated as appro-
priate. Resource utilization and charges were summarized
in two patient age groups: 50–64 years and 65 years and
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older. The total sample was divided into the following
three groups based on the setting in which the data/
encounters were observed: private practitioner only, hos-
pital only, and the combination. These descriptors inform
as to the data being presented (e.g., if a patient is observ-
able within the context of both private practitioner and
hospital data, only the relevant data is displayed per set-
ting). Not all patients were observable in both settings.
For assessment of outcomes associated with pertussis
and physician coding behaviors for pertussis, all diagno-
sis and procedure codes were extracted from each
unique patient’s record between the patient’s pertussis
episode of care (PEOC) start and end dates. Descriptive
analyses, including measures of central tendency and
variability, were reported as appropriate (e.g., mean
length of inpatient stay). The following outcomes and
associated variables were reported in both the pre-index
and post-index periods: outpatient visits (physician office
and outpatient hospital), emergency department visits,
hospital admissions, length of inpatient stay, intensive
care unit admission, assisted ventilation, acute respira-
tory distress syndrome, and post-index death.
Resource utilization was also summarized by PEOC for
the pre-index and post-index periods by age group (i.e.,
50–64 years and 65 years and older). Predefined diagnoses
and procedures associated with each encounter type (i.e.,
outpatient private practitioner offices plus hospital out-
patient clinics and sites; hospitalizations plus emergency
department visits) were reported. Mean visits per patient
were also reported for each encounter type.
In assessing the reported charges associated with in-
patient and outpatient healthcare utilization, total reported
charges for each diagnostic group and point of care setting
were calculated along with descriptive statistics. Charges
for visits, diagnostic imaging, laboratory tests, outpatient
respiratory/nebulizer procedures, and inpatient medica-
tions were reported. The mean charge per quantity within
a specific category (e.g., visits, diagnostic imaging, asthma
medications, etc.) was used to replace data points where
charge values were greater than 3 SD from the mean or
missing. All charges were adjusted to 2010 U.S. dollars,
using the Medical Care Consumer Price Index for All
Urban Consumers (CPI-U), specifically the medical ser-




The sample included 5,748 patients aged at least 50 years
with pertussis, of whom 5,490 were observed in the pri-
vate practitioner setting; 643 were observed in the hos-
pital setting; and 385 were observed in both settings.
The latter 385 patients were included in analyses for the
combined settings (private practitioner plus hospital) as
well as in the individual private practitioner and hospital
strata.
Twenty four patients were excluded from the analysis
due to unknown gender and 1,691 patients were excluded
from the analysis because they were not observed in the
database at least three months before the index date and
either at least 3 months after the index date or with a rec-
ord of death, reducing our confidence of complete data
capture. A valid age was associated with each patient in
the sample. Additionally, 2,651 patients with a positive
pertussis laboratory test were excluded from the analysis
because they lacked a corresponding medical claim for a
pertussis related diagnosis during the 14 days before or
after specimen collection.
Approximately two-thirds of patients within the total
sample were female [Χ2(1,N = 5,748) = 698.68, p < .0001]
(Table 1). Most patients were from the southern and
western U.S. census regions. ANOVA results indicated
patient age was significantly different according to the
type of first confirmation of pertussis (i.e., ICD-9 code
033.0, 033.9, 484.3 or a positive pertussis laboratory test)
[F(3, 5744) = 47.42, p < .0001]. Bonferroni adjusted post
hoc comparisons revealed a significantly older group of
patients whose initial pertussis confirmation was a diagno-
sis of pneumonia in whooping cough (i.e., ICD-9 code
484.3; see Table 2). Length of episode of care was also sig-
nificantly different [F(3,5744) = 47.42 , p < .0001] with
patients whose first confirmation of pertussis was a positive
laboratory test having longer episodes of care (Table 2).
Incidence of pertussis (weighted sample)
Estimated national incidence of diagnosed pertussis ranged
from 2.1-4.6 cases per 100,000 people across the two age
groups (50–64 and ≥65) during the years 2006 to 2010
(Figure 1). Incidence per 100,000 increased over time from
3.0 in 2006 to 4.6 in 2010 for patients 50–64 years and from
2.9 in 2006 to 4.4 in 2010 for patients 65 years or older.
The ratio of IMS to NNDSS rates from the ≥65 age group
ranged from 2.86:1.15 (in 2006) to 3.31:0.28 (in 2008).
Diagnoses associated with pertussis
During the pre-index period, cough and bronchitis
(categorized as part of the larger lower respiratory tract in-
fection group) were the initial diagnoses most frequently
made before the pertussis diagnosis (Table 3). The major-
ity of patients who presented with a pertussis-like condi-
tion (e.g., cough) in the pre-index period had an acute
respiratory diagnosis (80% to 91%, depending on health-
care setting).
During the post-index period, pertussis and cough were
frequent diagnoses (Table 3). Additionally, in the private
practitioner setting, pneumonia diagnoses were observed in
10% and 19% of patients 50–64 and ≥65, respectively.
Within the hospital setting, pneumonia diagnoses were
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Table 1 Demographics and baseline clinical characteristics
Private practitioner setting Hospital setting Patients in both private practitioner
and hospital settings
Patient count % of Total Patient count % of Total Patient count % of Total
N 5,490 100 643 100 385 100
Gender
Male 1,779 32.4 238 37.0 145 37.7
Female 3,711 67.6 405 63.0 240 62.3
Age, years
50-64 3,523 64.2 402 62.5 242 62.9
50-54 1,276 23.2 132 20.5 76 19.7
55-59 1,175 21.4 132 20.5 75 19.5
60-64 1,072 19.5 138 21.5 91 23.6
≥65 1,967 35.8 241 37.5 143 37.1
65-69 731 13.3 89 13.8 54 14.0
70-74 503 9.2 67 10.4 42 10.9
≥75 733 13.4 85 13.2 47 12.2
Mean (SD) Age 63 (9) na 63 (9) na 61 (9) na
US Census Region
Midwest 1,042 19.0 96 14.9 54 14.0
Northeast 664 12.1 165 25.7 71 18,4
South 2,236 40.7 218 33.9 130 33.8
West 1,547 28.2 164 25.5 130 33.8
Payer Type
Commercial 4,137 75.4 467 72.6 281 73.0
Medicaid 87 1.6 26 4.0 16 4.2
Medicare 1,264 23.0 141 21.9 86 22.3
Year of Initial Diagnosis
2006 570 10.4 63 9.8 21 5.5
2007 659 12.0 63 9.8 30 7.8
2008 861 15.7 86 13.4 55 14.3
2009 1,587 28.9 203 31.6 132 34.3
2010 (Jan-Oct) 1,813 33.0 228 36.5 147 38.2
Length of Episode of Care, days
Mean (SD) 26 (32) na 28 (34) na 34 (37) na
Median (range) 16 (1–180) na 15 (1–180) na 23 (1–180) na
na = not applicable.
Census region information was not available for the entire study sample. A small percentage of patients had an unknown or other (e.g., TRICARE) insurer.
Therefore, patient counts above do not always sum to the total population per setting.
Table 2 Mean (95% confidence interval) age and episode of care length by type of initial pertussis confirmation
Initial pertussis confirmation Age, years Episode of care length, days
ICD-9 code 033.0 (whooping cough due to B. pertussis ), N = 573 61.30 (60.56-62.03) 21.41 (19.13-23.70)
ICD-9 code 033.9 (whooping cough, organism unspecified), N = 2,231 63.07 (62.70-63.47) 21.35 (20.14-22.55)
ICD-9 code 484.3 (pneumonia in whooping cough), N = 233 69.43 (68.01-70.86) 21.82 (17.61-26.03)
Lab test positive for B. pertussis , N = 2,711 61.74 (61.42-62.06) 31.17 (29.93-32.42)
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observed in 10% of patients in the younger age group and
17% of patients in the older age group. Of patients that
were observed in both private practitioner and hospital set-
tings, approximately 15% and 31% of patients aged 50–64
and ≥ 65, respectively, were diagnosed with pneumonia.
Healthcare charges and utilization
The average medical charges associated with diagnosed
pertussis ranged from $496 to $3,239 per patient in the
pre-index period and $987 to $16,971 per patient in the
post-index period. Table 4 shows data from all patients
grouped by the healthcare setting. Per patient resource
use and charges were consistently higher during the
post-index period than the pre-index period (Table 4).
During the pre-index period, average per patient charges
were slightly higher in the subgroup of 50 to 64 year old
patients than in the sample as a whole or in the subgroup ≥
65 year old patients; in the post-index period, the average
per patient charges for 50–64 year old patients tended to
be higher than those for ≥ 65 year old patients, particularly
among the combined private practitioner and hospital pa-
tient group (Table 4). Additional analysis found one or
more patients with disproportionately high utilization of
healthcare resources in the subgroup of 50 to 64 year old
patients which led to the observed increases in charges.
During the post-index period, among patients 50 to
64 years old, average per patient charges were $1,533 for
those in the private practitioner setting, $16,971 for those
in the hospital setting, and $15,062 for those represented
in both settings. During the post-index period, among
patients ≥ 65 years, for the same respective categories, the
average per patient charges were $987, $10,693, and
$7,102. During both the pre- and post-index periods, visit
charges and inpatient/ER medications dispensed consti-
tuted the bulk of the detailed charges (Table 4).
Discussion
To the authors’ knowledge, this study is the first to de-
scribe a large sample of adults 50 years and older with
pertussis. Consistent with prior findings [22-28], our
results suggest that under-reporting of pertussis cases
occurs despite nationwide mandates to notify health au-
thorities when cases are identified. We estimated the na-
tional incidence of diagnosed pertussis to be between 2.1
and 4.6 cases per 100,000 people across the two age
groups (50–64 and ≥65) during the years 2006 to 2010.
Figure 1 Estimated incidence of diagnosed pertussis (ICD-9 codes 033.0, 033.9, or 484.3) and reported incidence of pertussis
from NNDSS.
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Table 3 Most common diagnosis pre- and post-index, private practitioner setting
Diagnoses Patient count % of Total
Pre-Index Period
Total Unique Patients in the Population 5,490
Patients with ≥ 1 Pertussis-like event 3,140 57
Acute Respiratory: 2,857 52
COUGH 1,350 25
UPPER RESPIRATORY TRACT INFECTION 1,004 18
ACUTE BRONCHITIS 938 17
ASTHMA 449 8
ALLERGY 413 8
LOWER RESPIRATORY TRACT INFECTION 387 7
OTHER PNEUMONIA 313 6
Other : 1,798 33
HYPERTENSION 579 11
SHORTNESS OF BREATH 368 7
HIGH CHOLESTEROL 316 6
GERD 290 5
CHEST PAIN 266 5
COPD AND OTHER ALLIED CONDITIONS 229 4
DIABETES 224 4
LUMBAR STRAIN OR BACK PAIN 171 3
Post-Index Period
Total Unique Patients in the Population 5,490 100
Acute Respiratory: 5,053 92
WHOOPING COUGH-UNSPECIFIED ORGANISM 2,224 41
COUGH 2,222 40
UPPER RESPIRATORY TRACT INFECTION 770 14
ACUTE BRONCHITIS 694 13
WHOOPING COUGH-BORDETELLA PERTUSSIS 605 11
ASTHMA 551 10
OTHER PNEUMONIA 468 9
ALLERGY 404 7
LOWER RESPIRATORY TRACT INFECTION 359 7
PNEUMONIA IN WHOOPING COUGH 237 4
Other: 2,309 42
HYPERTENSION 851 16
HIGH CHOLESTEROL 495 9
SHORTNESS OF BREATH 445 8
DIABETES 421 8
GERD 421 8
COPD AND OTHER ALLIED CONDITIONS 388 7
CHEST PAIN 300 5
Patients may be counted in multiple types of diagnoses. Therefore, the sum of the sub-classifications may total more than the total unique patients.
Diagnoses in >2% of patients are listed.
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Table 4 Healthcare resource utilization and charges observed during the pre-index and post-index periods by healthcare setting
Both private practitioner and hospital patient mean
(SE)
Private practitioner only patient mean (SE) Hospital only patient mean
(SE)
Total 50-64 Years >65 Years Total 50-64 Years >65 Years Total 50-64 Years >65 Years
(N = 385) (N = 242) (N = 143) (N = 5,490) (N = 3,523) (N = 1,967) (N = 643) (N = 402) (N = 241)
Panel A: Pre-Index Resource Utilization
Outpatient
Visits 2.1 (0.2) 2.4 (0.3) 1.6 (0.2) 1.6 (0.0) 2.7 (0.1) 1.7 (0.1) 0.2 (0.0) 0.2 (0.0) 0.3 (0.1)
Diagnostic imaging 0.3 (0.0) 0.4 (0.1) 0.3 (0.1) 0.3 (0.0) 0.3 (0.0) 0.3 (0.0) 0.1 (0.0) 0.1 (0.0) 0.1 (0.0)
Lab tests 0.3 (0.1) 0.3 (0.1) 0.2 (0.1) 0.3 (0.0) 0.3 (0.0) 0.3 (0.0) 0.0 (0.0) 0.0 (0.0) 0.0 (0.0)
Respiratory
treatments
0.4 (0.1) 0.4 (0.1) 0.2 (0.1) 0.3 (0.0) 0.4 (0.0) 0.2 (0.0) 0.0 (0.0) 0.0 (0.0) 0.0 (0.0)
Inpatient (including emergency department data)
Visits 0.1 (0.0) 0.1 (0.0) 0.1 (0.0) na na na 0.1 (0.0) 0.1 (0.0) 0.1 (0.0)
Diagnostic imaging 0.1 (0.0) 0.1 (0.0) 0.1 (0.1) na na na 0.1 (0.0) 0.1 (0.0) 0.1 (0.0)
Lab tests 0.1 (0.0) 0.1 (0.1) 0.0 (0.0) na na na 0.1 (0.0) 0.0 (0.0) 0.1 (0.0)
Medications 9.8 (5.3) 10.5 (7.7) 8.7 (5.7) na na na 9.5 (3.3) 7.4 (4.7) 12.9 (4.4)
Systemic antibiotics 1.2 (0.8) 1.2 (1.1) 1.3 (1.2) na na na 0.9 (0.5) 0.7 (0.7) 1.1 (0.8)
Asthma 0.8 (0.4) 0.8 (0.5) 0.6 (0.6) na na na 0.7 (0.3) 0.6 (0.3) 0.8 (0.4)
All other
medications





















Table 4 Healthcare resource utilization and charges observed during the pre-index and post-index periods by healthcare setting (Continued)
Panel B: Pre-Index Charges, 2010 Dollars
Outpatient
Visits 420 (37.4) 470 (49.0) 331 (55.6) 225 (9.4) 214 (6.5) 244 (23.5) 228 (25.9) 226 (29.7) 230 (48.4)
Diagnostic imaging 50 (7.2) 55 (9.0) 43 (12.0) 35 (1.9) 38 (2.5) 30 (2.9) 38 (6.3) 37 (6.0) 39 (13.7)
Lab tests 15 (6.0) 19 (9.3) 9 (3.8) 12 (0.9) 13 (1.1) 10 (1.4) 4 (1.7) 5 (2.6) 2 (1.5)
Respiratory
treatments
25 (4.7) 31 (6.8) 14 (5.2) 19 (1.2) 23 (1.7) 13 (1.5) 0 (0.0) 0 (0.0) 0 (0.0)
All other 371 (101.4) 434 (140.3) 263 (134.6) 76 (4.7) 76 (5.7) 78 (8.4) 345 (83.4) 312 (92.3) 399 (160.9)
All Outpatient
Charges
932 (130.1) 1,080 (172.7) 683 (192.2) 497 (48.4) 496 (62.0) 499 (77.2) 892 (103.3) 907 (117.9) 868 (193.6)
Inpatient (including emergency department data)
Visits 284 (115.9) 296 (135.8) 265 (211.8) na na na 322 (81.6) 270 (87.0) 409 (162.5)
Diagnostic imaging 38 (15.8) 33 (15.6) 48 (33.5) na na na 38 (10.1) 33 (10.2) 48 (20.9)
Lab tests 12 (9.6) 18 (15.2) 2 (1.8) na na na 9 (5.8) 11 (9.1) 5 (2.7)
Medications 364 (214.3) 337 (271.9) 410 (349.5) na na na 0 (0.0) 229 (164.2) 409 (220.0)
Systemic antibiotics 160 (106.7) 118 (107.3) 231 (223.0) na na na 296 (131.6) 71 (64.6) 177 (135.1)
Asthma 27 (13.9) 30 (17.9) 22 (22.2) na na na 111 (64.7) 19 (10.8) 25 (14.5)
All other
medications
177 (102.7) 189 (150.5) 157 (108.2) na na na 21 (8.7) 138 (91.5) 207 (80.0)
All other charges 691 (293.0) 722 (406.6) 639 (387.9) na na na 164 (64.5) 557 (248.5) 1,500 (502.3)
All Inpatient
Charges
1,390 (635.5) 1,406 (836.0) 1,364 (966.1) na na na 1,576 (446.2) 1,099 (509.9) 2,372 (832.0)
All Inpatient and
Outpatient Charges





















Table 4 Healthcare resource utilization and charges observed during the pre-index and post-index periods by healthcare setting (Continued)
Panel C: Post-Index Resource Utilization
Outpatient
Visits 2.9 (0.2) 3.0 (0.3) 2.8 (0.3) 2.4 (0.0) 2.3 (0.1) 2.5 (0.1) 0.5 (0.1) 0.5 (0.1) 0.6 (0.1)
Diagnostic imaging 0.5 (0.1) 0.5 (0.1) 0.4 (0.1) 0.4 (0.0) 0.4 (0.0) 0.4 (0.0) 0.2 (0.0) 0.2 (0.0) 0.2 (0.0)
Lab tests 0.6 (0.1) 0.6 (0.1) 0.5 (0.1) 0.6 (0.0) 0.7 (0.0) 0.5 (0.0) 0.3 (0.0) 0.3 (0.1) 0.3 (0.1)
Respiratory
treatments
0.5 (0.1) 0.6 (0.1) 0.4 (0.1) 0.5 (0.0) 0.5 (0.0) 0.4 (0.0) 0.0 (0.0) 0.0 (0.0) 0.0 (0.0)
Inpatient (including emergency department data)
Visits 0.3 (0.0) 0.3 (0.1) 0.3 (0.0) na na na 0.4 (0.0) 0.4 (0.0) 97 (0.0)
Diagnostic imaging 0.6 (0.2) 0.7 (0.3) 0.4 (0.1) na na na 0.7 (0.1) 0.8 (0.2) 134 (0.1)
Lab tests 0.9 (0.2) 0.9 (0.3) 0.9 (0.3) na na na 1.0 (0.1) 0.9 (0.2) 261 (0.2)
Medications 59.9 (15.3) 72.5 (23.5) 38.5 (10.1) na na na 95.9 (24.7) 114.8 (38.9) 15,497 (10.9)
Systemic antibiotics 6.4 (2.9) 8.8 (4.6) 2.4 (0.7) na na na 6.1 (1.8) 7.3 (2.9) 981 (0.8)
Asthma 7.5 (2.4) 8.5 (3.7) 5.7 (1.8) na na na 6.6 (1.5) 6.5 (2.3) 1,593 (1.3)
All other
medications





















Table 4 Healthcare resource utilization and charges observed during the pre-index and post-index periods by healthcare setting (Continued)
Panel D: Post-Index Charges, 2010 Dollars
Outpatient
Visits 626 (45.9) 632 (59.0) 615 (72.8) 331 (7.5) 324 (8.8) 344 (13.5) 489 (45.5) 469 (44.5) 523 (95.7)
Diagnostic imaging 91 (13.8) 82 (15.3) 107 (26.8) 52 (2.5) 56 (3.3) 46 (3.6) 51 (6.6) 44 (6.4) 61 (13.7)
Lab tests 36 (5.3) 38 (6.6) 33 (8.9) 26 (1.4) 31 (2.1) 17 (1.4) 29 (4.9) 32 (6.6) 25 (7.2)
Respiratory
treatments
39 (7.3) 48 (10.7) 25 (7.8) 32 (1.8) 37 (2.5) 23 (2.2) 0 (0.0) 0 (0.0) 0 (0.0)
All other 514 (112.5) 460 (113.5) 603 (233.2) 94 (50.0) 101 (6.8) 82 (6.8) 600 (101.7) 560 (102.1) 668 (210.2)
All Outpatient
Charges
1,436 (167.0) 1,378 (181.1) 1,519 (329.7) 1,337 (195.9) 1,533 (299.3) 987 (106.7) 1,576 (146.0) 1,554 (146.2) 1,613 (304.2)
Inpatient (including emergency department data)
Visits 2,162 (413.2) 2,533 (624.7) 1,535 (343.3) na na na 2,460 (327.6) 2,427 (472.6) 2,516 (376.4)
Diagnostic imaging 157 (31.0) 184 (46.6) 111 (26.9) na na na 230 (44.9) 256 (68.8) 186 (33.9)
Lab tests 127 (32.4) 149 (49.1) 90 (26.6) na na na 140 (23.0) 145 (34.0) 133 (23.3)
Medications 2,106 (595.6) 2,917 (937.4) 734 (195.1) na na na 2,652 (615.5) 3,423 (972.8) 1,366 (233.6)
Systemic antibiotics 422 (139.2) 571 (218.7) 171 (54.6) na na na 530 (140.6) 646 (220.5) 338 (72.2)
Asthma 182 (52.3) 209 (78.2) 136 (48.3) na na na 155 (32.7) 160 (48.2) 147 (33.7)
All other
medications
1,502 (443.9) 2,137 (699.6) 427 (125.5) na na na 1,967 (479.0) 2,617 (757.9) 881 (186.0)
All other charges 6,117 (1,752.1) 7,893 (2,745.5) 3,112 (773.4) na na na 7,560 (1,742.8) 9,167 (2,748.1) 4,881 (759.1)
All Inpatient
Charges
10,669 (2,710.9) 13,675 (4,237.2) 5,582 (1,284.0) na na na 13,042 (2,627.6) 15,417 (4,122.6) 9,080 (1,342.5)
All Inpatient and
Outpatient Charges





















By contrast, the ratios of IMS to NNDSS incidence rates
were greater than one in each of the five years analyzed
supporting the hypothesis that pertussis infections in
older adults occur more frequently than previously
reported. Although larger than NNDSS estimates, we
suspect our estimated incidence of diagnosed pertussis is
still an understatement of the true rate of diagnosed per-
tussis cases as patients who tested positive for pertussis
but did not have a private practitioner claim with an
ICD-9-CM code for pertussis and patients that were
only observed in the hospital setting were not accounted
for in the incidence calculation. While infants and young
children bear a well-documented burden caused by Borde-
tella pertussis, this disease’s direct financial and health
burden is not exclusive to childhood as once previously
thought. The increasing incidence of pertussis among the
older adults in this study is consistent with studies in ado-
lescents and younger adults, among whom the incidence
of pertussis also appears to be increasing [11,14-18].
Our observation that females with pertussis represented
a significantly higher proportion of the total sample com-
pared to males is consistent with results in younger
patient populations [22,23] and behavioral (i.e., treatment-
seeking) literature [29,30]. The age effect on the initial
diagnosis of pneumonia in whooping cough suggests that
susceptibility to pneumonia and/or a pneumonia diagnosis
may increase as age increases. Regarding the finding of
significantly longer episodes of care among patients whose
initial pertussis confirmations were made through positive
laboratory tests, we interpret that this is related to severity.
That is, a sicker patient may be more likely to undergo la-
boratory testing.
The results of this study also suggest that pertussis is not
always diagnosed on the first occasion that the patient pre-
sents for care. This finding has been previously reported
[e.g., 27–28]. Cough and acute bronchitis were the most
common conditions diagnosed prior to the pertussis diag-
nosis. Over half (57%) of the sample had one or more visits
with at least one pertussis-like diagnosis in the period im-
mediately preceding the index pertussis diagnosis. These
initial diagnoses may have been made while practitioners
awaited laboratory confirmation of etiology or they may
have been misdiagnoses. If the latter is true, misdiagnosed
patients that remain untreated represent a potential source
of transmission to others. Under diagnosis of pertussis in
older patients may occur because healthcare providers con-
tinue to view pertussis as a childhood disease [14]. These
results underscore the need to heighten healthcare pro-
vider awareness of the occurrence of pertussis in adults,
including older adults.
The average charges associated with a diagnosed pertus-
sis episode of care ranged from $496 to $3,239 per patient
in the pre-index period and $987 to $16,971 per patient in
the post-index period. When the average episode of care
charges from patients observed in the private practitioner
setting ($1,834) are applied to the average annual inci-
dence estimate between 2006 and 2010 (1,513 cases), the
extrapolated value approaches 3 million U.S. dollars.
Within some categories (e.g., visits, lab tests, medications)
the observed charges were greater in the younger age
group (i.e., 50–64 years old) compared to the older (i.e., 65
+ years old) age group. This result was driven by a minor-
ity of patients in the 50–64 year old group with very high
healthcare utilization (and thus charges). Additionally,
there were more patients in the younger group with
asthma which may have led to the observation of increased
utilization of respiratory/nebulizer treatments and medica-
tions. It is also possible that physicians are more likely to
order lab tests for younger patients or that younger
patients delay seeking care for a longer period of time and
as a result present with more severe cases necessitating
additional healthcare resources.
The use of charges is a proxy for the direct medical
costs and represents the upper bound of the direct cost
of physician office and hospital encounters from the
current study. Historical direct medical costs (i.e., 2002
US$) of adult pertussis cases in the U.S. obtained from
published literature range from $181 to $5,310 per pa-
tient depending on a number of factors including geo-
graphic location, population and type of services
examined [31,32]. Additionally, while not studied here,
the indirect costs for the patients and their caregivers
should also be considered in the societal economic
burden.
The results of this study are subject to at least four
limitations. First, with the exception of the projected in-
cidence rates of ICD-9-CM coded pertussis from private
practitioners, the data analyzed in the current study may
not be generalizeable to the entire nation as it is an
unweighted convenience sample obtained for the pur-
pose of describing pertussis episodes of care. Second,
charges were used as a measure of a portion of the eco-
nomic burden. Because charges for healthcare services
are typically higher than reimbursed amounts, charges
reflected in the current study are likely to be higher than
the costs paid by health insurers and patients. Third,
claims data can be inherently limiting because they are
collected for billing and reimbursement purposes, rather
than for research purposes. This particular limitation
may have yielded an underestimate of the projected inci-
dence of diagnosed pertussis if practitioners are reluc-
tant to submit a claim with a pertussis code in absence
of laboratory confirmation, or ‘under’ code for other rea-
sons. In addition, if a diagnosis were confirmed by a la-
boratory result after a claim was submitted, a physician
would not submit a second claim as reimbursement
would not be affected. Finally, it is likely that the meth-
ods used to diagnose pertussis (i.e., clinical and/or
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laboratory evaluations) in this study are not always 100%
sensitive and/or 100% specific potentially yielding impre-
cise results. The retrospective, observational nature of the
study also should be considered when interpreting the
results as it could make the results subject to selection bias.
To our knowledge, potential biases may include an under-
representation of patients receiving care when a reimburse-
ment claim is not submitted (e.g., patients without health
insurance), underrepresentation of patients consulting pro-
viders that do not submit medical claims electronically as
well as any miscoding, none of which could be identified
or corrected for in this analysis. Strengths of the study in-
clude the large sample size and the national representative-
ness of the weighted sample and the inclusion of patient
data from multiple care settings (i.e., private practitioners,
hospitals, and laboratories).
Conclusions
The results of this study suggest that the incidence of
diagnosed pertussis is greater than what is reported
through the national surveillance system (i.e., NNDSS),
and appears to have increased over recent years among
adults 50 years and older. The portion of the economic
impact measured (i.e., charges) was between $1,835 and
$14,428 over the episode of patient care from the time of
first presentation with symptoms until clinical care was no
longer sought. The results support the need for greater
clinical awareness, as well as better prevention and control
efforts to reduce the burden of pertussis in adults. Such
efforts may, in turn, decrease the transmission to other
populations where the potential for substantial morbidity
and mortality exists (e.g., infants). Additional research in
older adult populations is warranted to further substanti-
ate the current findings.
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